Last reviewed · How we verify
TAA06 injection
At a glance
| Generic name | TAA06 injection |
|---|---|
| Sponsor | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma (PHASE1)
- A Clinical Trial of TAA06 Injection in Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAA06 injection CI brief — competitive landscape report
- TAA06 injection updates RSS · CI watch RSS
- PersonGen BioTherapeutics (Suzhou) Co., Ltd. portfolio CI